[1-(氨基甲基)环戊基]乙酸 | 60142-99-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: [1-(氨基甲基)环戊基]乙酸
• 英文名称: Gababutin
• 英文别名: 1-aminomethyl-1-cyclopentane acetic acid；(1-aminomethyl-cyclopentane)acetic acid；2-[1-(aminomethyl)cyclopentyl]acetic acid
• CAS: 60142-99-6
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: MKGSCDBHUPQQMX-UHFFFAOYSA-N

物化性质

• 沸点：
  298.4±13.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 [1-(氨基甲基)环戊基]乙酸 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 Boc-Gbn
  参考文献：
  名称：

  Oxadiazolone bioisosteres of pregabalin and gabapentin

  摘要：

  A series of oxadiazolone bioisosteres of pregabalin 1 and gabapentin 2 were prepared, and several were found to exhibit similar potency for the alpha(2)-delta subunit of voltage-gated calcium channels. Oxadiazolone 9 derived from 2 achieved low brain uptake but was nevertheless active in models of osteoarthritis. The high clearance associated with compound 9 was postulated to be a consequence of efflux by OAT and/or OCT, and was attenuated on co-administration with cimetidine or probenecid. (C) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2008.10.101

文献信息

• Prodrugs of GABA analogs, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20060229361A1

  公开（公告）日：2006-10-12

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，GABA类似物前药的药物组合物以及制备GABA类似物前药的方法。本发明还提供了使用GABA类似物前药的方法以及使用GABA类似物前药的药物组合物治疗或预防常见疾病和/或疾病的方法。
• The merger of decatungstate and copper catalysis to enable aliphatic C(sp3)–H trifluoromethylation
  作者：Patrick J. Sarver、Vlad Bacauanu、Danielle M. Schultz、Daniel A. DiRocco、Yu-hong Lam、Edward C. Sherer、David W. C. MacMillan

  DOI：10.1038/s41557-020-0436-1

  日期：2020.5

  enables the direct conversion of both strong aliphatic and benzylic C-H bonds into the corresponding C(sp3)-CF3 products in a single step using a bench-stable, commercially available trifluoromethylation reagent. The reaction requires only a single equivalent of substrate and proceeds with excellent selectivity for positions distal to unprotected amines. To demonstrate the utility of this new methodology

  三氟甲基（CF3）基团的引入可以显着改善化合物的生物学特性。尽管三氟甲基化的化合物已确立的重要性，但是用于烷基CH键的三氟甲基化的通用方法仍然难以实现。在这里，我们报告通过光驱动，decatungstate催化的氢原子转移和铜催化的合并发展双重催化的C（sp3）-H三氟甲基化。这种金属光氧化还原方法可使用稳定的市售三氟甲基化试剂，一步就将强脂族和苄基CH键直接转化为相应的C（sp3）-CF3产品。该反应仅需要单当量的底物，并且对于未保护的胺远端的位置具有优异的选择性。为了证明这种新方法在后期功能化中的实用性，我们直接衍生了各种已获批准的药物和天然产品，以生成有价值的三氟甲基化类似物。初步的机械实验表明，在此过程中形成了“ Cu-CF3”物质，并且关键的C（sp3）-CF3键形成步骤涉及铜催化剂。
• Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
  申请人：——

  公开号：US20030083382A1

  公开（公告）日：2003-05-01

  The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.

  本发明提供了加巴喷丁及其他GABA类似物的前药的延长释放口服剂型，这些剂型表现出较低的毒性。这些剂型特别适用于给予那些被代谢形成醛类物质的加巴喷丁及其他GABA类似物的前药。本发明的剂型适用于治疗或预防已知父体加巴喷丁或其他GABA类似物在治疗上有效的疾病和/或疾病。
• Fused bicyclic or tricyclic amino acids
  申请人：Pfizer Inc.

  公开号：US20030078300A1

  公开（公告）日：2003-04-24

  The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.

  本发明的化合物是双环或三环氨基酸，在治疗癫痫、晕厥发作、运动减少、头颅疾病、神经退行性疾病、抑郁症、焦虑、恐慌、疼痛、关节炎、神经病理性疾病、睡眠障碍、内脏疼痛疾病和胃肠疾病方面具有用处。包括用于制备最终产品和在过程中有用的中间体的方法。还包括含有一种或多种这些化合物的药物组合物。
• Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
  申请人：Roark Howard William

  公开号：US20050004177A1

  公开（公告）日：2005-01-06

  This invention relates to a combination of an allosteric inhibitor of matrix metalloproteinase-13, or a pharmaceutically acceptable salt thereof, and a ligand to an alpha-2-delta receptor, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the combination, and a method of using the combination to treat a disease or disorder in a mammal suffering therefrom, wherein the disease or disorder is responsive to treatment in one aspect by an allosteric inhibitor of MMP-13 and in the same or a different aspect by a ligand to an alpha-2-delta receptor.

  这项发明涉及一种基质金属蛋白酶-13的变构抑制剂，或其药用盐，以及α-2-δ受体的配体，或其药用盐的组合，包括该组合的药物组合物，以及使用该组合来治疗哺乳动物患有的疾病或紊乱的方法，其中该疾病或紊乱在一方面通过MMP-13的变构抑制剂治疗，在另一方面或不同方面通过α-2-δ受体的配体治疗。